ES2332687B1 - Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. - Google Patents

Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. Download PDF

Info

Publication number
ES2332687B1
ES2332687B1 ES200800736A ES200800736A ES2332687B1 ES 2332687 B1 ES2332687 B1 ES 2332687B1 ES 200800736 A ES200800736 A ES 200800736A ES 200800736 A ES200800736 A ES 200800736A ES 2332687 B1 ES2332687 B1 ES 2332687B1
Authority
ES
Spain
Prior art keywords
4pba
disease
treatment
pharmaceutically acceptable
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES200800736A
Other languages
English (en)
Spanish (es)
Other versions
ES2332687A1 (es
Inventor
Ana Maria Garcia Osta
Luis Alberto Perez Mediavilla
Diana Sara Frechilla Manso
Ana Lourdes Ricobaraza Abarquero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200800736A priority Critical patent/ES2332687B1/es
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Priority to CA2718463A priority patent/CA2718463A1/en
Priority to US12/921,933 priority patent/US20110027251A1/en
Priority to PCT/ES2009/000121 priority patent/WO2009112609A1/es
Priority to MX2010009933A priority patent/MX2010009933A/es
Priority to JP2010550224A priority patent/JP2011518119A/ja
Priority to EP09719846A priority patent/EP2272515A1/en
Priority to AU2009224613A priority patent/AU2009224613A1/en
Priority to BRPI0909745A priority patent/BRPI0909745A2/pt
Priority to RU2010138638/15A priority patent/RU2010138638A/ru
Priority to CN2009801183670A priority patent/CN102036665A/zh
Publication of ES2332687A1 publication Critical patent/ES2332687A1/es
Application granted granted Critical
Publication of ES2332687B1 publication Critical patent/ES2332687B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES200800736A 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. Withdrawn - After Issue ES2332687B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES200800736A ES2332687B1 (es) 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
BRPI0909745A BRPI0909745A2 (pt) 2008-03-13 2009-03-06 novos usos de 4-fenil butirato de sódio (4pba) e de seus sais farmaceuticamente aceitáveis
PCT/ES2009/000121 WO2009112609A1 (es) 2008-03-13 2009-03-06 Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables
MX2010009933A MX2010009933A (es) 2008-03-13 2009-03-06 Nuevos usos del 4-fenilbutirato de sodio (4pba) y sus sales farmaceuticamente aceptables.
JP2010550224A JP2011518119A (ja) 2008-03-13 2009-03-06 ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途
EP09719846A EP2272515A1 (en) 2008-03-13 2009-03-06 Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof
CA2718463A CA2718463A1 (en) 2008-03-13 2009-03-06 Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts
US12/921,933 US20110027251A1 (en) 2008-03-13 2009-03-06 Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts
RU2010138638/15A RU2010138638A (ru) 2008-03-13 2009-03-06 Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей
CN2009801183670A CN102036665A (zh) 2008-03-13 2009-03-06 4-苯基丁酸钠(4pba)及其药学上可接受的盐的新颖用途
AU2009224613A AU2009224613A1 (en) 2008-03-13 2009-03-06 Novel uses of sodium 4-phenylbutyrate (4 PBA) and the pharmaceutically acceptable salts thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200800736A ES2332687B1 (es) 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.

Publications (2)

Publication Number Publication Date
ES2332687A1 ES2332687A1 (es) 2010-02-10
ES2332687B1 true ES2332687B1 (es) 2011-01-10

Family

ID=40691368

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200800736A Withdrawn - After Issue ES2332687B1 (es) 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.

Country Status (11)

Country Link
US (1) US20110027251A1 (enExample)
EP (1) EP2272515A1 (enExample)
JP (1) JP2011518119A (enExample)
CN (1) CN102036665A (enExample)
AU (1) AU2009224613A1 (enExample)
BR (1) BRPI0909745A2 (enExample)
CA (1) CA2718463A1 (enExample)
ES (1) ES2332687B1 (enExample)
MX (1) MX2010009933A (enExample)
RU (1) RU2010138638A (enExample)
WO (1) WO2009112609A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080827A1 (es) * 2010-04-06 2012-05-09 Bayer Cropscience Ag Utilizacion del acido 4- fenil- butirico y/o de sus sales para el aumento de la tolerancia al estres en plantas
CN101973868B (zh) * 2010-11-12 2012-08-15 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅰ型结晶及其制备方法
EP2599479A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment of alzheimer's disease
WO2013149091A1 (en) 2012-03-29 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Composition and method for treating neurodegenerative disease
CN102757334B (zh) * 2012-07-30 2014-05-28 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅱ型晶体及其制备方法
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
US11224668B2 (en) * 2016-02-29 2022-01-18 Neurovation Labs, Inc. Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD
IL296490B1 (en) 2016-03-15 2025-09-01 Acer Therapeutics Inc Tasty compositions containing sodium phenylbutyrate and their uses
JP6962572B2 (ja) * 2016-03-18 2021-11-05 学校法人同志社 ２，４−ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
JP2020083827A (ja) * 2018-11-27 2020-06-04 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
WO2020139874A1 (en) * 2018-12-27 2020-07-02 Virginia Polytechnic Institute And State University Chemically programmed neutrophils and uses thereof
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US20240108593A1 (en) * 2020-12-07 2024-04-04 University Of Miami Method of treating polyamine imbalance-related disorders
JP2024543053A (ja) * 2021-11-08 2024-11-19 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
CN116099003A (zh) * 2022-11-28 2023-05-12 核工业总医院 内质网应激抑制剂在放射性认知功能障碍药物中的应用
WO2024165757A1 (en) 2023-02-10 2024-08-15 Ludwig-Maximilians-Universität München Oral phenylbutyrate for treatment of human 4-repeat tauopathies
CN117338763A (zh) * 2023-11-01 2024-01-05 重庆医科大学 丁酸钠在制备治疗帕金森病的药物中的应用及其治疗新靶标

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
WO2002090534A1 (en) * 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE69706566T2 (de) * 1996-08-13 2002-07-11 P.N. Gerolymatos S.A., Kruoneri Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
WO2002090534A1 (en) * 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLENNOW, K. y col. Alzheimer´s disease. The Lancet. 2006, Vol. 368, N$^{o}$ 9533, páginas 387-403, ISSN 0140-6736. Página 398 tabla 2. *
DE FELICE, F.G. y col. Inhibition of Alzheimer´s disease beta- amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. The FASEB Journal. 2001, Vol. 15, N$^{o}$ 7, páginas 1297-1299, ISSN 0892-6638. Todo el documento. *
FINDEIS, M.A. The role of amyloid Beta peptide 42 in Alzheimer's desease. Pharmacology & Therapeutics. 2007, Vol. 116, N$^{o}$ 2 páginas 266-286, ISSN 0163-7258. Página 274, apartado 3.4.2. \\ Y Página 280, párrafo 2$^{o}$. *
SALLOWAY, S. y col. Disease-modifying therapies in Alzheimer's disease. Alzheimer's & Dementia. 2008, Vol. 4, N$^{o}$ 2, páginas 65-79, ISSN 1552-5260. Página 73, columna derecha, párrafo 3. \\ Y Página 69, párrafo 1.8. Página 67, tabla 1. *

Also Published As

Publication number Publication date
JP2011518119A (ja) 2011-06-23
US20110027251A1 (en) 2011-02-03
CN102036665A (zh) 2011-04-27
WO2009112609A1 (es) 2009-09-17
CA2718463A1 (en) 2009-09-17
ES2332687A1 (es) 2010-02-10
BRPI0909745A2 (pt) 2019-09-24
MX2010009933A (es) 2010-12-06
RU2010138638A (ru) 2012-04-20
EP2272515A1 (en) 2011-01-12
AU2009224613A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
ES2332687B1 (es) Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
Doig et al. Inhibition of protein aggregation and amyloid formation by small molecules
Parry et al. Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure
ES2627933T3 (es) Péptido y el uso del mismo
JP2022535644A (ja) 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法
Li et al. HDAC3 inhibitor (BRD3308) modulates microglial pyroptosis and neuroinflammation through PPARγ/NLRP3/GSDMD to improve neurological function after intraventricular hemorrhage in mice
US20120316247A1 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
ES2853974T3 (es) Uso de una composición que contiene benzoato en trastornos del ciclo de la urea y trastornos neurodegenerativos
Sarode et al. Cerebrolysin reduces excitotoxicity by modulation of cell-death proteins in delayed hours of ischemic reperfusion injury
CN108451954A (zh) Fg-4592或其盐的新用途以及药品和保健品
Shao et al. Huang-Pu-Tong-Qiao Formula Alleviates Hippocampal Neuron Damage by Inhibiting NLRP3 Inflammasome-mediated Pyroptosis in Alzheimer’s Disease
JP2024543056A (ja) エダラボンデクスボルネオール含有組成物の認知障害の治療における応用
He et al. SIRT1 mediates H2S-ameliorated diabetes-associated cognitive dysfunction in rats: Possible involvement of inhibiting hippocampal endoplasmic reticulum stress and synaptic dysfunction
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
KR20230013116A (ko) 신경보호 유도용 화합물 및 조성물
WO2019148471A1 (zh) Fg-4592或其盐的新用途以及药品和保健品
ES2357934B2 (es) Uso de un espirolido analogos y derivados para el tratamiento y/o la prevencion de patologias relacionadas con las proteinas tau y b-amiloide.
TWI465234B (zh) Ｐｉｐｏｘｏｌａｎ之新穎用途及基於此新穎用途的藥學組合物
US20160136229A1 (en) Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
ES2896224T3 (es) Composición farmacéutica que comprende arginina para su uso en el tratamiento de la enfermedad de PolyQ
ES2357284A1 (es) Utilizacion de la gimnodimina, analogos y derivados para el tratamiento y/o la prevencion de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide.
CN102319237A (zh) 槲皮素在制备nlrp3炎症小体抑制药物中的应用
WO2017178685A1 (es) Tratamiento de enfermedades neurodegenerativas
Zhou et al. Vitamin D3 alleviates AD-like pathology in APP/PS1 mice by inhibiting pyroptosis and neuroinflammation via DJ-1/PARK7
WO2024165757A1 (en) Oral phenylbutyrate for treatment of human 4-repeat tauopathies

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20100210

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2332687

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20101227

FA2A Application withdrawn

Effective date: 20110517